Peptides for Osteoporosis
The peptides people most often research for osteoporosis, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.
- Peptides listed
- 5
- With human trials
- 1
- FDA approved (any use)
- 1
- RetatrutideGLP-1 / GIP / glucagon triple agonistNo study with an outcome for osteoporosisPubMed search, 2 Oct 2026Human2Animal1Summarised0Investigational · phase 3Overview
- BPC-157Gastric pentadecapeptideNo study with an outcome for osteoporosisPubMed search, 11 Oct 2026Human1Animal2Summarised0PCAC voted 8–6 for 503A (Jul 2026)For osteoporosisOverview
- TB-500Synthetic fragment of thymosin beta-4No study with an outcome for osteoporosisPubMed search, 11 Oct 2026Human1Animal0Summarised0PCAC voted 8–6 for 503A (Jul 2026)For osteoporosisOverview
- MOTS-cMitochondrial-derived peptideAnimal evidence, 2 of 4Biochemical and biophysical research communications 2016, PMID 27237975Human2Animal2Summarised2PCAC voted 7–5 for 503A (Jul 2026)For osteoporosisOverview
- TirzepatideGLP-1 / GIP dual agonistHuman observational evidence, 3 of 4Diabetes research and clinical practice 2025, PMID 41218687Human15Animal0Summarised1FDA approved (Mounjaro, Zepbound)For osteoporosisOverview
What this list does not show
Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.
Search interest is not evidence
This list follows what people search for and discuss. It says nothing about how well any peptide works.Animal results may not carry over
Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.Approval covers specific uses
An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.Combinations are a separate question
Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.What osteoporosis is
MedlinePlus describes osteoporosis as a disease that makes bones weak and likely to fracture.[26]
It calls osteoporosis a 'silent' disease because it doesn't usually cause symptoms.[26]
Bone evidence for the listed peptides
PubMed records matching the site's bone search (a search hit is not a bone-density result): Retatrutide 2 human-only and 1 animal-only; BPC-157 1 human-only and 2 animal-only; TB-500 1 human-only and 0 animal-only; MOTS-c 2 human-only and 2 animal-only; Tirzepatide 15 human-only and 0 animal-only.
Calculated from goal osteoporosis; ledger date 2026-10-02; counts retatrutide (human only 2, animal 1, rct 0), bpc-157 (human only 1, animal 2, rct 0), tb-500 (human only 1, animal 0, rct 0), mots-c (human only 2, animal 2, rct 0), tirzepatide (human only 15, animal 0, rct 0). Formula: Copied from web/src/data/goals.json: peptides[].ledger.humanOnly.n and ledger.animal.n for this goal (PubMed title/abstract search, humans[mh] NOT animals vs animals NOT humans).
A large retrospective cohort found tirzepatide associated with a higher risk of osteoporosis or fragility fracture than other GLP-1 drugs (hazard ratio 1.44, 95% CI 1.22-1.69); the design shows association, not cause.[2]
For MOTS-c the bone data are in ovariectomized mice, where treatment significantly alleviated bone loss on micro-CT.[1]
A cell study found MOTS-c increased type I collagen synthesis in cultured human osteoblasts, which is laboratory evidence rather than a patient result.[27]
Common questions
Can peptides increase bone density?
The supportive bone results cited here are in ovariectomized mice and cultured cells for MOTS-c.[1]
Does tirzepatide affect fracture risk?
One retrospective cohort reported a higher risk of osteoporosis or fragility fracture with tirzepatide than with other GLP-1 drugs; being observational, it shows association only.[2]
Explore nearby goals
Sources
- 1Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation.Biochemical and biophysical research communications · 2016PMID 27237975Accessed 2 Oct 2026
- 2Association of tirzepatide use with risk of osteoporosis compared with other GLP-1 receptor agonists: A retrospective cohort study using the TriNetX database.Diabetes research and clinical practice · 2025PMID 41218687Accessed 2 Oct 2026
- 3PubMed search: retatrutide[tiab] OR LY3437943[tiab] (197 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 4PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (96 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (obesity[tiab] OR diabetes[tiab] OR liver[tiab] OR osteoarthritis[tiab]) AND "Clinical Trial"[pt] (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: (SYNCHRONIZE[tiab] OR TRIUMPH[tiab] OR GLORY[tiab] OR DREAMS[tiab]) AND (survodutide[tiab] OR retatrutide[tiab] OR mazdutide[tiab]) (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: "BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab] (230 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: "BPC-157"[tiab] AND humans[mh] (52 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (patients[tiab] OR clinical trial[pt] OR randomized[tiab]) (25 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (colitis[tiab] OR inflammatory bowel[tiab]) (48 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (tendon[tiab] OR ligament[tiab] OR muscle[tiab] OR bone[tiab] OR arthritis[tiab]) (58 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (nerve[tiab] OR neuropath*[tiab] OR spinal[tiab] OR liver[tiab] OR wound[tiab] OR burn[tiab]) (90 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) (1199 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (humans[mh] OR patients[tiab]) (678 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (randomized[tiab] OR clinical trial[pt]) (18 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 19PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (wound[tiab] OR dermal[tiab] OR skin[tiab] OR hair[tiab]) (212 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 20PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (tendon[tiab] OR muscle[tiab] OR cardiac[tiab] OR myocardial[tiab] OR heart[tiab]) (246 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 21PubMed search: "TB-500"[tiab] OR TB500[tiab] OR "Ac-LKKTETQ"[tiab] (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 22PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (57 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 23PubMed search: ("BPC-157"[tiab] OR "BPC 157"[tiab]) AND (human[tiab] OR patient*[tiab] OR volunteer*[tiab]) AND (adverse[tiab] OR safety[tiab] OR "side effects"[tiab]) (19 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 24PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab] OR RGN-259[tiab] OR RGN-137[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (61 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 25PubMed search: ("RGN-259"[tiab] OR "RGN-137"[tiab] OR "thymosin beta 4"[tiab]) AND (eye[tiab] OR ophthalmic[tiab] OR neurotrophic[tiab] OR cornea*[tiab]) AND (patients[tiab] OR trial[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 26Official web pageOfficial web page · web page
- 27MOTS-c improves osteoporosis by promoting the synthesis of type I collagen in osteoblasts via TGF-β/SMAD signaling pathway.European review for medical and pharmacological sciences · 2019PMID 31081069Accessed 2 Oct 2026
Found an error? Report a correction.